BACKGROUND: The population effects of influenza vaccination in children have not been extensively studied, especially in tropical, developing countries. In rural Senegal, we assessed the total (primary objective) and indirect effectiveness of a trivalent inactivated influenza vaccine (IIV3). METHODS: In this double-blind, cluster-randomized trial, villages were randomly allocated (1:1) for the high-coverage vaccination of children aged 6 months through 10 years with either the 2008-09 northern hemisphere IIV3 or aninactivated polio vaccine (IPV). Vaccinees were monitored for serious adverse events. All village residents, vaccinated and unvaccinated, were monitored for signs and symptoms of influenza illness using weekly home visits and surveillance in designated clinics. The primary outcome was all laboratory-confirmed symptomatic influenza. RESULTS:Between 23 May and 11 July 2009, 20 villages were randomized, and 66.5% of age-eligible children were enrolled (3918 in IIV3 villages and 3848 in IPV villages). Follow-up continued until 28 May 2010. There were 4 unrelated serious adverse events identified. Among vaccinees, the total effectiveness against illness caused by the seasonal influenza virus (presumed to all be drifted A/H3N2, based on antigenic characterization data) circulating at high rates among children was 43.6% (95% confidence interval [CI] 18.6-60.9%). The indirect effectiveness against seasonal A/H3N2 was 15.4% (95% CI -22.0 to 41.3%). The total effectiveness against illness caused by the pandemic influenza virus (A/H1N1pdm09) was -52.1% (95% CI -177.2 to 16.6%). CONCLUSIONS: IIV3 provided statistically significant, moderate protection to children in Senegal against circulating, pre-2010 seasonal influenza strains, but not against A/H1N1pdm09, which was not included in the vaccine. No indirect effects were measured. Further study in low-resource populations is warranted. CLINICAL TRIALS REGISTRATION: NCT00893906.
RCT Entities:
BACKGROUND: The population effects of influenza vaccination in children have not been extensively studied, especially in tropical, developing countries. In rural Senegal, we assessed the total (primary objective) and indirect effectiveness of a trivalent inactivated influenza vaccine (IIV3). METHODS: In this double-blind, cluster-randomized trial, villages were randomly allocated (1:1) for the high-coverage vaccination of children aged 6 months through 10 years with either the 2008-09 northern hemisphere IIV3 or an inactivated polio vaccine (IPV). Vaccinees were monitored for serious adverse events. All village residents, vaccinated and unvaccinated, were monitored for signs and symptoms of influenza illness using weekly home visits and surveillance in designated clinics. The primary outcome was all laboratory-confirmed symptomatic influenza. RESULTS: Between 23 May and 11 July 2009, 20 villages were randomized, and 66.5% of age-eligible children were enrolled (3918 in IIV3 villages and 3848 in IPV villages). Follow-up continued until 28 May 2010. There were 4 unrelated serious adverse events identified. Among vaccinees, the total effectiveness against illness caused by the seasonal influenza virus (presumed to all be drifted A/H3N2, based on antigenic characterization data) circulating at high rates among children was 43.6% (95% confidence interval [CI] 18.6-60.9%). The indirect effectiveness against seasonal A/H3N2 was 15.4% (95% CI -22.0 to 41.3%). The total effectiveness against illness caused by the pandemic influenza virus (A/H1N1pdm09) was -52.1% (95% CI -177.2 to 16.6%). CONCLUSIONS: IIV3 provided statistically significant, moderate protection to children in Senegal against circulating, pre-2010 seasonal influenza strains, but not against A/H1N1pdm09, which was not included in the vaccine. No indirect effects were measured. Further study in low-resource populations is warranted. CLINICAL TRIALS REGISTRATION: NCT00893906.
Authors: Mark C Steinhoff; Joanne Katz; Janet A Englund; Subarna K Khatry; Laxman Shrestha; Jane Kuypers; Laveta Stewart; Luke C Mullany; Helen Y Chu; Steven C LeClerq; Naoko Kozuki; Monica McNeal; Adriana M Reedy; James M Tielsch Journal: Lancet Infect Dis Date: 2017-05-15 Impact factor: 25.071
Authors: Timo Vesikari; Markus Knuf; Peter Wutzler; Aino Karvonen; Dorothee Kieninger-Baum; Heinz-Josef Schmitt; Frank Baehner; Astrid Borkowski; Theodore F Tsai; Ralf Clemens Journal: N Engl J Med Date: 2011-10-13 Impact factor: 91.245
Authors: Varsha K Jain; Luis Rivera; Khalequ Zaman; Roberto A Espos; Chukiat Sirivichayakul; Beatriz P Quiambao; Doris M Rivera-Medina; Pirunghul Kerdpanich; Mehmet Ceyhan; Ener C Dinleyici; Alejandro Cravioto; Mohammed Yunus; Pornthep Chanthavanich; Kriengsak Limkittikul; Zafer Kurugol; Emre Alhan; Adrian Caplanusi; Serge Durviaux; Philippe Boutet; Opokua Ofori-Anyinam; Vijayalakshmi Chandrasekaran; Ghassan Dbaibo; Bruce L Innis Journal: N Engl J Med Date: 2013-12-11 Impact factor: 91.245
Authors: Mbayame Niang; Meagan E Deming; Deborah Goudiaby; Ousmane M Diop; Ndongo Dia; Aldiouma Diallo; Justin R Ortiz; Doudou Diop; Kristen D C Lewis; Kathryn E Lafond; Marc-Alain Widdowson; John C Victor; Kathleen M Neuzil Journal: Vaccine Date: 2020-10-02 Impact factor: 3.641
Authors: Gail E Potter; Nicole Bohme Carnegie; Jonathan D Sugimoto; Aldiouma Diallo; John C Victor; Kathleen M Neuzil; M Elizabeth Halloran Journal: J R Stat Soc Ser C Appl Stat Date: 2021-09-22 Impact factor: 1.680
Authors: Mbayame Nd Niang; Jonathan D Sugimoto; Aldiouma Diallo; Bou Diarra; Justin R Ortiz; Kristen D C Lewis; Kathryn E Lafond; M Elizabeth Halloran; Marc-Alain Widdowson; Kathleen M Neuzil; John C Victor Journal: Clin Infect Dis Date: 2021-06-15 Impact factor: 9.079
Authors: Ryan E Malosh; Joshua G Petrie; Amy Callear; Rachel Truscon; Emileigh Johnson; Richard Evans; Latifa Bazzi; Caroline Cheng; Mark S Thompson; Emily T Martin; Arnold S Monto Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 20.999
Authors: Gail E Potter; Jimmy Wong; Jonathan Sugimoto; Aldiouma Diallo; John C Victor; Kathleen Neuzil; M Elizabeth Halloran Journal: PLoS One Date: 2019-08-06 Impact factor: 3.240